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Abstract: Research over the past decade has indicated that melanocortin peptides are 
potent inhibitors of inflammation and a promising source of new anti-inflammatory and 
cytoprotective therapies. The purpose of the present paper is to compare protective effects 
of α-, β-, and γ-melanocyte stimulating hormone on acetaminophen induced liver lesions in 
male CBA mice. Acetaminophen was applied intragastrically in a dose of 150 mg/kg, and 
tested substances were applied intraperitoneally 1 hour before acetaminophen. Mice were 
sacrificed after 24 hours and intensity of liver injury was estimated by measurement of 
plasma transaminase activity (AST and ALT) and histopathological grading of lesions. It 
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was found that α-, β-, and γ-MSH decrease intensity of lesions by both criteria in a dose-
dependent manner.  
Keywords: melanocortins; alpha-MSH; beta-MSH; gamma-MSH; acetaminophen; liver 
 
1. Introduction 
Acute and chronic inflammatory disorders of the liver are among the greatest challenges of 
hepatology [1]. Despite some progress in the prevention and pharmacotherapy of such conditions, the 
development of more effective drugs is still expected [2]. Research over the past decade indicates that 
melanocortin peptides are potent inhibitors of inflammation and a promising source of new anti-
inflammatory and cytoprotective therapies [3,4]. The most investigated peptide from this group is α-
melanocyte stimulating hormone (α-MSH), which exhibits anti-inflammatory effects in a different 
animal models of acute and chronic inflammation [2,3,5–10]. α-MSH is generated by proteolysis from 
larger precursor hormone called proopiomelanocortin (POMC) [3,4]. POMC is the source of other 
bioactive hormones that share structural homology with α-MSH, including ACTH, β-MSH, and  
γ-MSH. Peptide sequences of the natural melanocortins are listed in Scheme 1. 
Scheme 1. Peptide sequences of ACTH, α-MSH, β-MSH, and γ-MSH. The common amino 
acid motif sequence (HFRW) is depicted by bold characters [3,4]. 
ACTH           SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF 
α-MSH          SYSMEHFRWGKPV 
β-MSH          AEKKDEGPYRMEHFRWGSPPKD 
γ-MSH          YVMGHFRWDRFG 
 
Melanocortins exert their effects by activating melanocortin receptors, leading to adenyl cyclase 
activation and subsequent increase of intracellular cAMP concentration [3,4]. This prevents activation 
of nuclear factor κB, and subsequently leads to reduction of pro-inflammatory mediators synthesis and 
adhesion molecules expression [3,4] There are five different melanocortin receptor subtypes (MC-1R 
to MC-5R) with a sequence homology of 39–61% and a different affinity for the natural melanocortin 
peptides [3,4] and their receptors (Table 1). β-MSH is an agonist for MC-1R, MC-3R and MC-4R 
[11,12]. The purpose of the present paper is to compare protective effects of α-, β-, and γ-MSH on 
acetaminophen induced liver lesions in male CBA mice, a standard screening procedure for potential 
hepatoprotective drugs. Beneficial effects of α-MSH have been observed in models of liver fibrosis 
and necroinflammation [13–16]. However, there are no data concerning the role and effects of β- and 
γ-MSH in necroinflammatory liver lesions. Acetaminophen (APAP) produces liver lesions via its 
reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) [17]. Covalent binding of NAPQI leads 
to disruption of important intracellular proteins and to damage of centrilobular regions of liver after 
overdose [18]. The loss of cellular integrity is accompanied with the release of intracellular content 
possessing proinflammatory and hydrolytic capabilities, and a subsequent liberation of numerous 
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cytokine and chemokine mediators from nonparenchymal and nonhepatic cell types [17]. The most 
prominent proinflammatory mediators in APAP-mediated liver injury are TNF, Fas, interleukin 6, 8, 
and 11, leukemia inhibitory factor, oncostatin M, and macrophage migration inhibitory factor, MIP-2, 
MCP-1 [17]. Also, the influx of activated cells such as macrophages, neutrophils, and monocytes 
contributes to the complexity of events [17]. The final result is the strong inflammatory response of the 
liver [17].  
Table 1. Melanocortin receptor subtypes and affinity of their ligands [3,4]. 
Receptor 
subtype 
Affinity of agonists 
MC-1R α-MSH > ACTH >> γ-MSH
MC-2R ACTH 
MC-3R γ-MSH = ACTH ≥ α-MSH 
MC-4R α-MSH = ACTH >> γ-MSH
MC-5R α-MSH ≥ ACTH > γ-MSH 
2. Results and Discussion 
The effects of α-, β-, and γ-MSH in APAP-mediated liver injury were estimated by measurement of 
plasma transaminase activity and histopathological grading of liver lesions [19–23]. 
2.1. Plasma transaminase activity 
The results of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity in 
plasma 24 hours after APAP administration suggest that all tested substances (α-, β-, and γ-MSH) have 
protective effects (Table 2 and Table 3). 
Table 2. Aspartate aminotransferase activity (U/L) in plasma 24 h after acetaminophen 
administration (150 mg/kg i.g.). Tested substances were given intraperitoneally 1 h before 
acetaminophen. P value is a result of comparison with the control group (Steel’s test). 
Substance Mean SD  Median P value 
Control 0.9% NaCl 6767.3 6468.6 5434.0  
α-MSH 6 × 10-8 mol/kg* 4880.4 3891.4 3691.0 0.998 
α-MSH 3 × 10-7 mol/kg* 2613.9 1114.9 2368.5 0.999 
α-MSH 6 × 10-7 mol/kg* 1418.5 1228.4 905.5 0.398 
α-MSH 1.5 × 10-6 mol/kg* 539.5 459.6 414.0 0.017 
α-MSH 3 × 10-6 mol/kg 8845.0 8311.0 7788.0 0.995 
β-MSH 5 × 10-8 mol/kg 881.9 900.4 669.5 0.145 
β-MSH 1 × 10-7 mol/kg 182.0 49.3 181.5 0.003 
β-MSH 2 × 10-7 mol/kg 578.5 268.6 446.0 0.030 
β-MSH 4 × 10-7 mol/kg 894.4 954.4 459.0 0.070 
γ-MSH 5 × 10-8 mol/kg 252.1 197.9 173.5 0.004 
γ-MSH 1 × 10-7 mol/kg 135.3 17.6 138.0 0.003 
γ-MSH 2 × 10-7 mol/kg 197.4 63.2 175.0 0.003 
γ-MSH 4 × 10-7 mol/kg 506.3 344.7 473.5 0.023 
* Turčić et al. [23]. 
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Table 3. Alanine aminotransferase activity (U/L) in plasma 24 h after acetaminophen 
administration (150 mg/kg i.g). Tested substances were given intraperitoneally 1 h before 
acetaminophen. P value is a result of comparison with the control group (Steel’s test). 
Substance Mean SD  Median P value 
Control 0.9% NaCl 9550.0 9213.2 7321.5  
α-MSH 6 × 10-8 mol/kg* 8983.7 4654.4 7901.0 0.962 
α-MSH 3 × 10-7 mol/kg* 4292.0 1422.1 3945.0 0.999 
α-MSH 6 × 10-7 mol/kg* 2671.3 2235.1 2167.5 0.390 
α-MSH 1.5 × 10-6 mol/kg* 585.8 1424.1 89.0 0.012 
α-MSH 3 × 10-6 mol/kg 16853.0 10676.0 18100.0 0.397 
β-MSH 5 × 10-8 mol/kg 2766.5 2693.6 2119.0 0.270 
β-MSH 1 × 10-7 mol/kg 55.3 17.7 56.5 0.003 
β-MSH 2 × 10-7 mol/kg 811.4 440.6 808.5 0.003 
β-MSH 4 × 10-7 mol/kg 2368.5 3033.9 1322.0 0.041 
γ-MSH 5 × 10-8 mol/kg 107.8 52.0 82.0 0.003 
γ-MSH 1 × 10-7 mol/kg 75.8 23.5 82.5 0.003 
γ-MSH 2 × 10-7 mol/kg 85.1 37.5 80.5 0.003 
γ-MSH 4 × 10-7 mol/kg 340.4 216.0 340.0 0.003 
* Turčić et al. [23].  
 
It must be observed that the protective effect of tested substances has the U-shaped dose-response, a 
common finding in the field of peptide research [24]. The optimal protective dose for the α-MSH was 
1.5 × 10-6 mol/kg, for β-MSH 1 × 10-7 mol/kg, and 1 × 10-7 mol/kg for γ-MSH. The increase in dose 
was followed by diminishing of protective effects. This finding is usually explained as a result of non-
specific binding of tested substance to other receptors and molecules. 
2.2. Histopathological analysis of liver lesions 
Histopathological analysis of liver lesions is considered as the gold standard when defining 
protective or toxical effects [25]. Two scales were used to grade presence and intensity of liver lesions. 
The first scale is based on grading of the liver lesions from 0-5, proposed by Silva et al. [21]. The 
second scale is based on the first scale, but simply considers sections with scores ≥3 as significant liver 
lesions [21,22]. Results of the histopathological grading are presented in Table 4, Table 5, and  
Figure 1. Both scales confirm results of the transaminase activity, and the U-shaped dose-responses are 
also observed.  
The optimal protective dose of α-MSH was 1.5 × 10-6 mol/kg, for β-MSH 1 × 10-7 mol/kg, and  
1 × 10-7 for γ-MSH. This data confirm the hepatoprotective effects of α-MSH observed in previously 
published papers [13–16], but also suggest that potency and efficacy of β- and γ-MSH in this model 
may even surpass that of α-MSH. 
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Table 4. Intensity of liver lesions 24 h after acetaminophen administration (150 mg/kg 
i.g.). Tested substances were given intraperitoneally 1 h before acetaminophen. P value is a 
result of comparison with the control group (Steel’s test). 
Substance Mean SD  Median P value 
Control 0.9% NaCl 4.00 1.20 4.5  
α-MSH 6 × 10-8 mol/kg* 4.17 0.98 4.5 0.999 
α-MSH 3 × 10-7 mol/kg* 3.33 0.52 3.0 0.5600 
α-MSH 6 × 10-7 mol/kg* 2.29 0.49 2.0 0.0320 
α-MSH 1.5 × 10-6 mol/kg* 2.00 0.76 2.0 0.0178 
α-MSH 3 × 10-6 mol/kg 5.00 0.0 5.0 0.456 
β-MSH 5 × 10-8 mol/kg 2.38 0.74 2.5 0.0471 
β-MSH 1 × 10-7 mol/kg 0.63 0.52 1.0 0.0021 
β-MSH 2 × 10-7 mol/kg 1.00 1.07 1.0 0.0043 
β-MSH 4 × 10-7 mol/kg 2.00 1.31 2.0 0.0410 
γ-MSH 5 × 10-8 mol/kg 1.00 0.54 1.0 0.0023 
γ-MSH 1 × 10-7 mol/kg 0.25 0.46 0.0 0.0019 
γ-MSH 2 × 10-7 mol/kg 0.25 0.46 0.0 0.0019 
γ-MSH 4 × 10-7 mol/kg 0.50 0.76 0.0 0.0026 
* Turčić et al. [23].  
Table 5. Number and percentage of animals with histopathology score ≥ 3, 24 h after 
acetaminophen administration (150 mg/kg i.g.). Tested substances were given 
intraperitoneally 1 h before acetaminophen. P value is a result of comparison with the 
control group (Fisher exact probability test). 
Substance Histopathology score ≥ 3 P value 
Control 0.9% NaCl 7/8 (87.5%)  
α-MSH 6 × 10-8 mol/kg 6/6 (100%) 0.999 
α-MSH 3 × 10-7 mol/kg 6/6 (100%) 0.560 
α-MSH 6 × 10-7 mol/kg 2/7 (28.6%) 0.032 
α-MSH 1.5 × 10-6 mol/kg 2/8 (25.0%) 0.018 
α-MSH 3 × 10-6 mol/kg 8/8 (100%) 0.999 
β-MSH 5 × 10-8 mol/kg 4/8 (50.0%) 0.047 
β-MSH 1 × 10-7 mol/kg 0/8 (0.00%) 0.002 
β-MSH 2 × 10-7 mol/kg 0/8 (0.00%) 0.004 
β-MSH 4 × 10-7 mol/kg 3/8 (37.5%) 0.041 
γ-MSH 5 × 10-8 mol/kg 0/8 (0.00%) 0.002 
γ-MSH 1 × 10-7 mol/kg 0/8 (0.00%) 0.002 
γ-MSH 2 × 10-7 mol/kg 0/8 (0.00%) 0.002 
γ-MSH 4 × 10-7 mol/kg 0/8 (0.00%) 0.003 
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Figure 1. Dose-response curve for α-, β-, and γ-MSH in a prevention of liver necrosis 
produced by acetaminophen (150 mg/kg i.g.).  
-10 -9 -8 -7 -6 -5
0
2
4
6
β-MSH
γ-MSH
α-MSH
Dose (log10 mol/kg)
In
te
ns
ity
 o
f l
iv
er
 le
si
on
s 
(s
ca
le
 0
-5
)
m
ea
n
± 9
5%
 c
on
fid
en
ce
 in
te
rv
al
 
 
α-MSH is the principal agonist with high affinity for all melanocortins receptors (except MC-2R) 
[3,4]. Affinity measures how strongly a ligand binds to a receptor, but in vivo tests determine whether 
a compound has the desired physiological effects [26]. We observed (Tables 2–5, Figure 1) that  
β-MSH and γ-MSH have much stronger hepatoprotective effects then α-MSH, using criteria of 
potency and efficacy [26,27]. In vivo order of β-MSH and γ-MSH potencies may be modified by 
several confounding factors including differences in metabolic degradation, and action via non-MC 
receptor mechanisms [28]. MC-3R is thought to be the only melanocortin receptor with sufficient 
affinity for γ-MSH. It is known to be present in the gut [12], but its presence in the liver of CBA mice 
remains to be determined. The use of selective antagonists could identify the role of individual 
melanocortins and their receptor subtypes (MC-1R - MC-5R) in acetaminophen-induced 
hepatotoxicity.  
 
3. Experimental 
 
3.1. Animals 
Male CBA mice, bred at Ruđer Bošković Institute, aged 12–16 weeks, were used in the experiment. 
They were maintained under standard laboratory conditions, with free access to water and 
commercially available murine food pellets (4RF21, Mucedola, Milan, Italy) 
3.2. Substances 
Pure acetaminophen (APAP) from the Krka pharmaceutical company (Novo Mesto, Slovenia) was 
used. APAP was dissolved in a warm saline (37 °C) under mild magnetic stirring. 
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α-MSH (Ac-SYSMEHFRWGKPV-NH2, GenScript, USA, purity > 95%) was used in five doses:  
6 × 10-8 mol/kg (0.1 mg/kg), 3 × 10-7 mol/kg (0.5 mg/kg), 6 × 10-7 mol/kg (1 mg/kg), 1.5 × 10-6 mol/kg 
(2.5 mg/kg) and 3 × 10-6 mol/kg (5 mg/kg). 
β-MSH (AEKKDEGPYRMEHFRWGSPPKD, GenScript, USA, purity > 95%) was used in four 
doses: 5 × 10-8 mol/kg (0.125 mg/kg), 1 × 10-7 mol/kg (0.25 mg/kg), 2 × 10-7 mol/kg (0.5 mg/kg) and  
4 × 10-7 mol/kg (1 mg/kg). 
γ1-MSH (YVMGHFRWDRF-NH2, GenScript, USA, purity > 95%) was used in four doses: 5 × 10-8 
mol/kg (0.075 mg/kg), 1 × 10-7 mol/kg (0.15 mg/kg), 2 × 10-7 mol/kg (0.3 mg/kg) and 4 × 10-7 mol/kg 
(0.6 mg/kg). 
Tested substances were dissolved in a warm (37 °C) saline solution. 
3.3. Treatment regimen 
Hepatitis was induced following the procedure described by Guarner et al., with slight 
modifications [19,20,23]. To induce hepatic drug-metabolizing enzymes mice were given 
phenobarbitone-sodium (Kemika, Zagreb, Croatia) in their drinking water for 7 days in a dose of  
0.3 g/L [18,20,23]. Thereafter, mice were fasted overnight and APAP (150 mg/kg) was given 
intragastrically (i.g.), via a gastric tube, in a volume of 0.5 mL. Mice were re-fed after 4 hours. All 
tested substances were given intraperitoneally (i.p.) 1 hour before APAP administration, in a volume 
of 0.2 mL. Control animals were treated with saline (0.9% NaCl). The size of experimental groups was 
6-8. Mice that spontaneously died were excluded from histopathological or biochemical analysis. 
3.4. Plasma transaminase activity 
Mice were sacrificed by decapitation 24 hours after APAP application. Heparin (250 U) was given 
intraperitoneally (i.p.) to each animal 15 minutes before sacrifice, and trunk blood was collected into 
heparinized tubes. Plasma was separated by centrifugation for 5 min at 8,000 g, and was stored at  
-20 °C for 24 h before transaminase activity determination. Alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) activity was determined by standard laboratory techniques. High 
standard deviations observed in the measurements of liver enzymes are typical for the experimental 
model of acetaminophen induced hepatotoxicity in mice, even in highly inbred animals [29,30]. 
Differences in the absorption and metabolism of acetaminophen between individual animals, changes 
in temperature, body weight and sampling of blood analytes are some of the contributing factors to 
high standard deviations of the measurements in small animal models [30]. However, acetaminophen 
is well suited to satisfy the criteria for an animal model both in terms of clinical relevance, cost, and 
dose-dependent toxicity [30]. 
3.5. Histopathological analysis of liver lesions 
Sections of the liver were fixed in 10% phosphate buffered formalin, embedded in paraffin, 
sectioned at 4 µm, and stained with hematoxilin and eosin (H&E). Sections were examined by using 
light microscope at magnification ×100. Two scales were used to grade presence and intensity of 
lesions [21–23].  
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The first scale is based on grades from 0–5: 
0. no lesions 
1. minimal lesions (individual or a few necrotic cells) 
2. mild lesions (10–25% necrotic cells or mild diffuse degenerative lesions) 
3. moderate lesions (25–40% necrotic or degenerative cells) 
4. marked lesions (40–50% necrotic or degenerative cells) 
5. severe lesions (more than 50% necrotic or degenerative cells) 
The second scale is based on the first scale, but simply considers sections with scores ≥ 3 as 
significant liver lesions [22]. 
3.6. Statistical analysis 
Plasma AST and ALT activity, as well as grade of lesions, are expressed as means, medians, and 
standard deviations. Difference between control and treated groups was determined using Steel's test. 
Difference between the groups in number of animals with histopathology score ≥ 3 was tested by using 
Fisher exact probability test. All applied tests were two-tailed. The results were considered significant 
if P-values were ≤ 0.05 [31]. Statistical analysis was made using KyPlot version 4 [32], and dose-
response curve was plotted using GraphPad Prism version 5 for Windows [33]. 
4. Conclusions 
Collected results of transaminase activity and histopathological grading suggest that α-, β, and γ-
melanocyte stimulating hormones prevent APAP-induced liver lesions. The hepatoprotective effect of 
α-MSH observed in previously published papers was confirmed [13–16]. However, potency and 
efficacy of β- and γ-MSH in this model may even surpass α-MSH. 
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